German pharma giant Boehringer Ingelheim is wagering up to $262 million on a discovery-stage project with the struggling Arena Pharmaceuticals, hoping to spotlight new treatments for central nervous system disorders.
Just a couple of weeks after booting company co-founder and CEO Jack Lief out of the company, a struggling Arena Pharmaceuticals has followed up with a move to ax 35% of its staff--some 80 jobs--while narrowing its R&D focus.
SINGAPORE-- Ildong Pharmaceuticals said South Korea's Ministry of Food and Drug Safety has granted approval for it to market the Arena Pharmaceuticals weight-loss drug, Belviq.
With a marketing push from partner Eisai behind it, Arena Pharmaceuticals more than doubled the revenue it earned from weight-loss drug Belviq in the last quarter but reported a Q3 loss of $10.7 million, or $0.05 per share.
The Japanese drugmaker Eisai, which is partnered with Arena Pharmaceuticals on the weight-loss pill Belviq, plans to add another 200 contract sales reps to its team.
Japanese drugmaker Eisai, which is partnered with Arena Pharmaceuticals on the weight-loss pill Belviq, plans to add another 200 contract sales reps to its team. On top of a new television ad push begun last month, the sales-force expansion is a one-two punch aimed at keeping prescription trends on the upswing.
Both Vivus and Arena marketing partner Eisai have partnered with healthcare benefits provider Aetna, which will integrate rival obesity drugs Qsymia and Belviq into a weight-loss lifestyle pilot program.
More than two years after Orexigen began a forced march back through a $100 million Phase III study for its weight drug Contrave, the biotech is back with the news that it scored the positive interim results it needs for a return trip to the FDA. And the drug developer says it can look ahead to a potential approval as early as June, 2014.
Eisai gave Arena Pharmaceuticals' obesity drug Belviq another vote of confidence. The Japanese drugmaker, already marketing the drug in the U.S., signed up to promote it in most other global markets, too. And it gave Arena a $60 million up-front payment to seal the deal.
Analysts promised a battle of obesity drugs between Arena's Belviq and Vivus' Qsymia. But in marketing partner Eisai, Arena has a weapon Vivus lacks--and that weapon is about to get bigger. The Japanese company plans to add more than 200 sales reps to its army by December, doubling its size since the drug hit the market this June.